Neeti Reddy, MD
Advanced Heart Failure and Transplant Cardiology · McAllen, TXNPI 1841636164
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,845 of the $23,723 with a category attached, or 75.2%. Roche Molecular Systems, Inc. accounts for 75.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $12,561 and has fallen 85.5% since, to $1,828 in 2025.
Across 115 payments — averaging $206.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Molecular Systems, Inc.$18K
- Abbott$2K
- Medtronic$906
- AstraZeneca$366
- Impulse Dynamics (USA) Inc.$334
- Abiomed$310
- plus $2K from 14 others
What the payments were for
- Consulting fees$17,84575%
- Travel & lodging$1,2545%
- Food & beverage$4,44119%
- Education$1831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Molecular Systems, Inc. | 34 | $17,845 |
| Abbott | 26 | $2,384 |
| Medtronic(2 entities) | 7 | $906 |
| AstraZeneca | 5 | $366 |
| Impulse Dynamics (USA) Inc. | 5 | $334 |
| Abiomed | 4 | $310 |
| Boston Scientific | 4 | $276 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $192 |
| Novartis | 8 | $176 |
| Amgen | 3 | $157 |
| Boehringer Ingelheim | 2 | $140 |
| E.r. Squibb & Sons, L.L.C. | 2 | $134 |
| Biotronik Inc. | 1 | $119 |
| Biosense Webster, Inc. | 2 | $109 |
| Atricure, Inc. | 1 | $103 |
| Chiesi USA, Inc. | 4 | $85 |
| Edwards Lifesciences | 1 | $35 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$648
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$590
- HeartMate 3 Left Ventricular Dev$293
- Impella$249
- OPTIMIZER SMART SYSTEM$169
- Mosaic$155
- JARDIANCE$124
- Repatha$124
- Watchman$120
- BRILINTA$119
- CAMZYOS$116
- ANDEXXA$116
- HeartMate 3 Left Ventricular Assist Device$115
- EMBLEM$108
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$103
- ATRICLIP LAA EXCLUSION SYSTEM$103
- SYNERGY ABLATION SYSTEM$103
How this compares
$23,723 in reported general payments places this provider in the 55th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 30 | $19,825 |
| FarxigaDapagliflozin Propanediol | 14 | $8,511 |
| Losartan Potassium | 43 | $422 |
| Nifedipine ErNifedipine | 11 | $264 |
| Atorvastatin Calcium | 41 | $176 |
| Metoprolol Succinate | 34 | $147 |
| Lisinopril | 15 | $118 |
| Carvedilol | 34 | $114 |
| Spironolactone | 17 | $114 |
| Ezetimibe | 11 | $79 |
| Rosuvastatin Calcium | 13 | $70 |
| Amlodipine Besylate | 14 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $176 | $19,82530 claims |
| AstraZenecaFarxiga | $366 | $8,51114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in McAllen
- Carlos GiraldoMcAllen$34K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
- Arvind BhimarajHouston$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.